New Delhi: In the realm of diabetes management, Ozempic has emerged as a transformative force, captivating patients and healthcare professionals alike
with its dual benefits for blood sugar control and weight loss. As India grapples with an escalating diabetes epidemic—affecting over 100 million adults—the arrival of Ozempic copycats signals a seismic shift. Patent expiry has unlocked the doors for affordable semaglutide generics, promising to democratise access to this groundbreaking GLP-1 receptor agonist. Imagine slashing monthly treatment costs from Rs 11,000 to as low as Rs 3,000; this is not a distant dream but an imminent reality reshaping diabetes treatment landscapes. With over 50 brands poised for launch, the stage is set for a price revolution that could redefine healthcare affordability.
This development arrives at a critical juncture, as India’s GLP-1 market surges amid rising obesity and type 2 diabetes prevalence. Branded therapies like Ozempic and Wegovy, once priced beyond reach for most, now face fierce competition from homegrown generics. What does this mean for patients seeking effective, cost-conscious diabetes solutions? Let us delve deeper into the mechanics of patent expiry and its profound implications.
Semaglutide patent expiry explained
Semaglutide, the active ingredient in Ozempic and Wegovy, saw its key Indian patent expire on 20 March 2026, ending Novo Nordisk’s exclusivity. This pivotal moment follows earlier composition patent lapses, paving the way for generic entry without legal hurdles. Indian courts had previously navigated related disputes, but the core protection’s end has triggered immediate launches.
The expiry aligns with global trends, though India leads as the first major market flooded with copycats, unlike delayed approvals elsewhere. This positions India as a generics powerhouse, exporting affordable options worldwide.
Branded Ozempic commanded Rs 8,800–11,000 monthly, rendering it inaccessible for many in a nation reliant on out-of-pocket expenses. Post-expiry generics from pioneers like Dr. Reddy’s, Sun Pharma, and Glenmark now retail at Rs 3,000–5,000 per month, with some dipping to Rs 1,290.
Experts forecast further drops to Rs 1,500–2,500 as competition intensifies, amplifying affordability for type 2 diabetes and obesity management. This 50–70% reduction could unlock a Rs 50,000 crore market opportunity.
